This company's experimental Alzheimer's disease drug looks very promising, but there are a few key caveats.
News & Analysis: Cassava Sciences, Inc.
Many are following these two stocks, which took hits on Wednesday.
Can this company's Alzheimer's disease candidate deliver further gains ahead?
Investors are betting this underdog will succeed where even the most reputable of biotech firms have failed.
The biotech's experimental Alzheimer's treatment could be a game changer.
These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
A public offering is weighing on the biophama's shares today.
A positive note from an investment bank about the biotech caught investors' attention.
Cassava's Alzheimer's disease drug candidate is turning heads.